Covalent Partners’s LumiraDx Limited Warrant LMDXW Stock Holding History

Covalent Partners’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-27,500	Closed	-$237	–	27
2023 Q4	$237	Hold	27,500	–	–	﹤0.01%	23
2023 Q3	$993	Hold	27,500	–	–	﹤0.01%	24
2023 Q2	$822	Hold	27,500	–	–	﹤0.01%	23
2023 Q1	$3.23K	Hold	27,500	–	–	0.01%	24
2022 Q4	$1.62K	Hold	27,500	–	–	﹤0.01%	29
2022 Q3	$3K	Hold	27,500	–	–	﹤0.01%	41
2022 Q2	$26K	Hold	27,500	–	–	0.03%	30
2022 Q1	$24K	Hold	27,500	–	–	0.02%	45
2021 Q4	$50K	Hold	27,500	–	–	0.04%	49
2021 Q3	$32K	Buy	+27,500	New	+$31.9K	0.05%	44

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Covalent Partners's LMDXW Position: Q1 2024 in Review

Covalent Partners sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2024, closing a stake of 27,500 shares — an estimated $237 sold.

Covalent Partners first reported a position in LMDXW in Q3 2021 and held it in 10 quarters. The position peaked at $50K in Q4 2021. 4 funds tracked by Wall St. Rank hold LMDXW as of Q1 2024.

Covalent Partners reported no remaining LumiraDx Limited Warrant position as of Q1 2024 after selling out during the quarter.
Covalent Partners sold 27,500 LumiraDx Limited Warrant shares in Q1 2024, an estimated $237.
Covalent Partners first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 10 quarters.
Covalent Partners's LumiraDx Limited Warrant position peaked at $50K in Q4 2021.
4 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2024.

Based on Covalent Partners's 13F filing for Q1 2024, filed 15 May 2024.